159 related articles for article (PubMed ID: 27553841)
1. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates.
Sadeghi N; Iacobelli M; Vaziri B; Kahn D; Hoppensteadt D; Guler N; Fareed J
Clin Appl Thromb Hemost; 2017 Apr; 23(3):211-220. PubMed ID: 27553841
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
4. Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product.
Sadeghi N; Kahn D; Syed D; Iqbal O; Abro S; Eshraghi R; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2014 Sep; 20(6):565-72. PubMed ID: 24651302
[TBL] [Abstract][Full Text] [Related]
5. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
6. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
7. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955
[TBL] [Abstract][Full Text] [Related]
9. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
10. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy.
Key NS; Christie B; Henderson N; Nelsestuen GL
Thromb Haemost; 2002 Jul; 88(1):60-5. PubMed ID: 12152680
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of recombinant activated factor VII: an update.
Hedner U
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
[TBL] [Abstract][Full Text] [Related]
13. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM
Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass.
Guzzetta NA; Szlam F; Kiser AS; Fernandez JD; Szlam AD; Leong T; Tanaka KA
Br J Anaesth; 2014 Feb; 112(2):319-27. PubMed ID: 24193321
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa does not induce hypercoagulability in vitro.
Gallistl S; Cvirn G; Muntean W
Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
17. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
18. Compositional differences in commercially available prothrombin complex concentrates.
Sadeghi N; Kahn D; Sayed D; Hoppenstadt D; Jeske W; Harenberg J; Dechristopher P; Fareed J
Clin Appl Thromb Hemost; 2014 Apr; 20(3):256-69. PubMed ID: 24288386
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Weeterings C; Lisman T; de Groot PG
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
